世界の多形神経膠芽腫(GBM)治療市場2020年:企業別、地域別、種類・用途別

【英語タイトル】Global Glioblastoma Multiforme (GBM) Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが出版した調査資料(GIR20SP03886)・商品コード:GIR20SP03886
・発行会社(調査会社):GlobalInfoResearch
・発行日:2020年9月18日(※2024年版があります。お問い合わせください)
・ページ数:106
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療、製薬、バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、多形神経膠芽腫(GBM)治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。多形神経膠芽腫(GBM)治療の種類別市場規模(化学療法、標的薬物療法、放射線療法)、用途別市場規模(病院、クリニック、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Merck、Sun Pharmaceuticals、Pfizer、Roche、Bristol-Myers Squibb、Arbor Pharmaceuticals、Emcure Pharmaceuticals、Amgen、AbbVie、Teva Pharmaceutical
・地域別グローバル市場分析 2015年-2020年
・多形神経膠芽腫(GBM)治療の北米市場(アメリカ、カナダ、メキシコ)
・多形神経膠芽腫(GBM)治療のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・多形神経膠芽腫(GBM)治療のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・多形神経膠芽腫(GBM)治療の南米市場(ブラジル、アルゼンチン)
・多形神経膠芽腫(GBM)治療の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:化学療法、標的薬物療法、放射線療法
・用途別分析:病院、クリニック、その他
・地域別市場規模予測 2021年-2025年
・調査の結果・結論
【レポートの概要】

Market Overview
The global Glioblastoma Multiforme (GBM) Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Glioblastoma Multiforme (GBM) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Glioblastoma Multiforme (GBM) Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Glioblastoma Multiforme (GBM) Therapeutics market has been segmented into:
Chemotherapy
Targeted Drug Therapy
Radiation Therapy

By Application, Glioblastoma Multiforme (GBM) Therapeutics has been segmented into:
Hospitals
Clinics
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Glioblastoma Multiforme (GBM) Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Glioblastoma Multiforme (GBM) Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Glioblastoma Multiforme (GBM) Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Glioblastoma Multiforme (GBM) Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Glioblastoma Multiforme (GBM) Therapeutics Market Share Analysis
Glioblastoma Multiforme (GBM) Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Glioblastoma Multiforme (GBM) Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Glioblastoma Multiforme (GBM) Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Glioblastoma Multiforme (GBM) Therapeutics are:
Merck
Sun Pharmaceuticals
Pfizer
Roche
Bristol-Myers Squibb
Arbor Pharmaceuticals
Emcure Pharmaceuticals
Amgen
AbbVie
Teva Pharmaceutical

【レポートの目次】

Table of Contents

1 Glioblastoma Multiforme (GBM) Therapeutics Market Overview
1.1 Product Overview and Scope of Glioblastoma Multiforme (GBM) Therapeutics
1.2 Classification of Glioblastoma Multiforme (GBM) Therapeutics by Type
1.2.1 Global Glioblastoma Multiforme (GBM) Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Type in 2019
1.2.3 Chemotherapy
1.2.4 Targeted Drug Therapy
1.2.5 Radiation Therapy
1.3 Global Glioblastoma Multiforme (GBM) Therapeutics Market by Application
1.3.1 Overview: Global Glioblastoma Multiforme (GBM) Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Glioblastoma Multiforme (GBM) Therapeutics Market by Regions
1.4.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Glioblastoma Multiforme (GBM) Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Glioblastoma Multiforme (GBM) Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Glioblastoma Multiforme (GBM) Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Glioblastoma Multiforme (GBM) Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Glioblastoma Multiforme (GBM) Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Glioblastoma Multiforme (GBM) Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Merck SWOT Analysis
2.1.4 Merck Product and Services
2.1.5 Merck Glioblastoma Multiforme (GBM) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Sun Pharmaceuticals
2.2.1 Sun Pharmaceuticals Details
2.2.2 Sun Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Sun Pharmaceuticals SWOT Analysis
2.2.4 Sun Pharmaceuticals Product and Services
2.2.5 Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Pfizer SWOT Analysis
2.3.4 Pfizer Product and Services
2.3.5 Pfizer Glioblastoma Multiforme (GBM) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Roche SWOT Analysis
2.4.4 Roche Product and Services
2.4.5 Roche Glioblastoma Multiforme (GBM) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Bristol-Myers Squibb SWOT Analysis
2.5.4 Bristol-Myers Squibb Product and Services
2.5.5 Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Arbor Pharmaceuticals
2.6.1 Arbor Pharmaceuticals Details
2.6.2 Arbor Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Arbor Pharmaceuticals SWOT Analysis
2.6.4 Arbor Pharmaceuticals Product and Services
2.6.5 Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 Emcure Pharmaceuticals
2.7.1 Emcure Pharmaceuticals Details
2.7.2 Emcure Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Emcure Pharmaceuticals SWOT Analysis
2.7.4 Emcure Pharmaceuticals Product and Services
2.7.5 Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 Amgen
2.8.1 Amgen Details
2.8.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Amgen SWOT Analysis
2.8.4 Amgen Product and Services
2.8.5 Amgen Glioblastoma Multiforme (GBM) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.9 AbbVie
2.9.1 AbbVie Details
2.9.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 AbbVie SWOT Analysis
2.9.4 AbbVie Product and Services
2.9.5 AbbVie Glioblastoma Multiforme (GBM) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.10 Teva Pharmaceutical
2.10.1 Teva Pharmaceutical Details
2.10.2 Teva Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Teva Pharmaceutical SWOT Analysis
2.10.4 Teva Pharmaceutical Product and Services
2.10.5 Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Glioblastoma Multiforme (GBM) Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Glioblastoma Multiforme (GBM) Therapeutics Players Market Share
3.2.2 Top 10 Glioblastoma Multiforme (GBM) Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Glioblastoma Multiforme (GBM) Therapeutics Revenue and Market Share by Regions
4.2 North America Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Glioblastoma Multiforme (GBM) Therapeutics Revenue by Countries
5.1 North America Glioblastoma Multiforme (GBM) Therapeutics Revenue by Countries (2015-2020)
5.2 USA Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue by Countries
6.1 Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Revenue by Countries
7.1 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Revenue by Countries (2015-2020)
7.2 China Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Glioblastoma Multiforme (GBM) Therapeutics Revenue by Countries
8.1 South America Glioblastoma Multiforme (GBM) Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Glioblastoma Multiforme (GBM) Therapeutics by Countries
9.1 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Glioblastoma Multiforme (GBM) Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Glioblastoma Multiforme (GBM) Therapeutics Market Forecast by Type (2019-2024)
10.3 Chemotherapy Revenue Growth Rate (2015-2025)
10.4 Targeted Drug Therapy Revenue Growth Rate (2015-2025)
10.5 Radiation Therapy Revenue Growth Rate (2015-2025)
11 Global Glioblastoma Multiforme (GBM) Therapeutics Market Segment by Application
11.1 Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Glioblastoma Multiforme (GBM) Therapeutics Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Others Revenue Growth (2015-2020)
12 Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Forecast (2021-2025)
12.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Forecast (2021-2025)
12.2 Global Glioblastoma Multiforme (GBM) Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Glioblastoma Multiforme (GBM) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Merck Corporate Information, Location and Competitors
Table 6. Merck Glioblastoma Multiforme (GBM) Therapeutics Major Business
Table 7. Merck Glioblastoma Multiforme (GBM) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 8. Merck SWOT Analysis
Table 9. Merck Glioblastoma Multiforme (GBM) Therapeutics Product and Solutions
Table 10. Merck Glioblastoma Multiforme (GBM) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Sun Pharmaceuticals Corporate Information, Location and Competitors
Table 12. Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Major Business
Table 13. Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Total Revenue (USD Million) (2018-2019)
Table 14. Sun Pharmaceuticals SWOT Analysis
Table 15. Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Product and Solutions
Table 16. Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Pfizer Corporate Information, Location and Competitors
Table 18. Pfizer Glioblastoma Multiforme (GBM) Therapeutics Major Business
Table 19. Pfizer Glioblastoma Multiforme (GBM) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 20. Pfizer SWOT Analysis
Table 21. Pfizer Glioblastoma Multiforme (GBM) Therapeutics Product and Solutions
Table 22. Pfizer Glioblastoma Multiforme (GBM) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Roche Corporate Information, Location and Competitors
Table 24. Roche Glioblastoma Multiforme (GBM) Therapeutics Major Business
Table 25. Roche Glioblastoma Multiforme (GBM) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 26. Roche SWOT Analysis
Table 27. Roche Glioblastoma Multiforme (GBM) Therapeutics Product and Solutions
Table 28. Roche Glioblastoma Multiforme (GBM) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 30. Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Major Business
Table 31. Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 32. Bristol-Myers Squibb SWOT Analysis
Table 33. Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Product and Solutions
Table 34. Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Arbor Pharmaceuticals Corporate Information, Location and Competitors
Table 36. Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Major Business
Table 37. Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 38. Arbor Pharmaceuticals SWOT Analysis
Table 39. Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Product and Solutions
Table 40. Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Emcure Pharmaceuticals Corporate Information, Location and Competitors
Table 42. Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Major Business
Table 43. Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 44. Emcure Pharmaceuticals SWOT Analysis
Table 45. Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Product and Solutions
Table 46. Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Amgen Corporate Information, Location and Competitors
Table 48. Amgen Glioblastoma Multiforme (GBM) Therapeutics Major Business
Table 49. Amgen Glioblastoma Multiforme (GBM) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 50. Amgen SWOT Analysis
Table 51. Amgen Glioblastoma Multiforme (GBM) Therapeutics Product and Solutions
Table 52. Amgen Glioblastoma Multiforme (GBM) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. AbbVie Corporate Information, Location and Competitors
Table 54. AbbVie Glioblastoma Multiforme (GBM) Therapeutics Major Business
Table 55. AbbVie Glioblastoma Multiforme (GBM) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 56. AbbVie SWOT Analysis
Table 57. AbbVie Glioblastoma Multiforme (GBM) Therapeutics Product and Solutions
Table 58. AbbVie Glioblastoma Multiforme (GBM) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Teva Pharmaceutical Corporate Information, Location and Competitors
Table 60. Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Major Business
Table 61. Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 62. Teva Pharmaceutical SWOT Analysis
Table 63. Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Product and Solutions
Table 64. Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 66. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Share by Players (2015-2020)
Table 67. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 68. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Regions (2015-2020)
Table 69. North America Glioblastoma Multiforme (GBM) Therapeutics Revenue by Countries (2015-2020)
Table 70. North America Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 71. Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 72. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 73. South America Glioblastoma Multiforme (GBM) Therapeutics Revenue by Countries (2015-2020)
Table 74. South America Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 75. Middle East and Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 76. Middle East and Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 77. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 78. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Share by Type (2015-2020)
Table 79. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Forecast by Type (2021-2025)
Table 80. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue by Application (2015-2020)
Table 81. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Share by Application (2015-2020)
Table 82. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Forecast by Application (2021-2025)
Table 83. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Glioblastoma Multiforme (GBM) Therapeutics Picture
Figure 2. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Type in 2019
Figure 3. Chemotherapy Picture
Figure 4. Targeted Drug Therapy Picture
Figure 5. Radiation Therapy Picture
Figure 6. Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Application in 2019
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Others Picture
Figure 10. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 11. North America Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. South America Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Middle East and Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Share by Players in 2019
Figure 18. Global Top 5 Players Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share in 2019
Figure 19. Global Top 10 Players Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share in 2019
Figure 20. Key Players Market Share Trend
Figure 21. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 22. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 23. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Regions in 2018
Figure 24. North America Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 25. Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 26. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. South America Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 28. Middle East and Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 29. North America Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 30. North America Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Countries in 2019
Figure 31. USA Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 32. Canada Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 33. Mexico Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 34. Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 35. Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Countries in 2019
Figure 36. Germany Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 37. UK Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. France Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. Russia Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 40. Italy Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 42. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Countries in 2019
Figure 43. China Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 44. Japan Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. Korea Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. India Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 47. Southeast Asia Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 48. South America Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 49. South America Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Countries in 2019
Figure 50. Brazil Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 51. Argentina Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 52. Middle East and Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 53. Middle East and Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Countries in 2019
Figure 54. Saudi Arabia Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 55. UAE Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. Egypt Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 57. South Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 58. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Share by Type (2015-2020)
Figure 59. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Share by Type in 2019
Figure 60. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share Forecast by Type (2021-2025)
Figure 61. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 62. Global Targeted Drug Therapy Revenue Growth Rate (2015-2020)
Figure 63. Global Radiation Therapy Revenue Growth Rate (2015-2020)
Figure 64. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Share by Application (2015-2020)
Figure 65. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Share by Application in 2019
Figure 66. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share Forecast by Application (2021-2025)
Figure 67. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 68. Global Clinics Revenue Growth Rate (2015-2020)
Figure 69. Global Others Revenue Growth Rate (2015-2020)
Figure 70. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 71. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 72. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 73. North America Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Forecast (2021-2025)
Figure 74. Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Forecast (2021-2025)
Figure 75. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Forecast (2021-2025)
Figure 76. South America Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Forecast (2021-2025)
Figure 77. Middle East and Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Forecast (2021-2025)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel


【掲載企業】

Merck、Sun Pharmaceuticals、Pfizer、Roche、Bristol-Myers Squibb、Arbor Pharmaceuticals、Emcure Pharmaceuticals、Amgen、AbbVie、Teva Pharmaceutical

★調査レポート[世界の多形神経膠芽腫(GBM)治療市場2020年:企業別、地域別、種類・用途別] (コード:GIR20SP03886)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の多形神経膠芽腫(GBM)治療市場2020年:企業別、地域別、種類・用途別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆